Literature DB >> 22673998

The secrets of the bone marrow niche: Metabolic priming for AML.

Rushdia Z Yusuf1, Ying-Hua Wang1, David T Scadden1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22673998      PMCID： PMC4013790          DOI： 10.1038/nm.2831

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   87.241


× No keyword cloud information.
  17 in total

1.  Therapy of secondary leukemia.

Authors:  J M Rowe
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

Review 2.  The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes.

Authors:  Arnold J Levine; Anna M Puzio-Kuter
Journal:  Science       Date:  2010-12-03       Impact factor: 47.728

3.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

Review 4.  Leukemias related to treatment with DNA topoisomerase II inhibitors.

Authors:  C A Felix
Journal:  Med Pediatr Oncol       Date:  2001-05

Review 5.  Therapy-related leukemia associated with alkylating agents.

Authors:  S M Davies
Journal:  Med Pediatr Oncol       Date:  2001-05

6.  Targeting HIF1α eliminates cancer stem cells in hematological malignancies.

Authors:  Yin Wang; Yan Liu; Sami N Malek; Pan Zheng; Yang Liu
Journal:  Cell Stem Cell       Date:  2011-04-08       Impact factor: 24.633

Review 7.  Clonal evolution in cancer.

Authors:  Mel Greaves; Carlo C Maley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

8.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

9.  Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.

Authors:  Taro Hitosugi; Sumin Kang; Matthew G Vander Heiden; Tae-Wook Chung; Shannon Elf; Katherine Lythgoe; Shaozhong Dong; Sagar Lonial; Xu Wang; Georgia Z Chen; Jianxin Xie; Ting-Lei Gu; Roberto D Polakiewicz; Johannes L Roesel; Titus J Boggon; Fadlo R Khuri; D Gary Gilliland; Lewis C Cantley; Jonathan Kaufman; Jing Chen
Journal:  Sci Signal       Date:  2009-11-17       Impact factor: 8.192

Review 10.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728
View more
  6 in total

Review 1.  Chemical metabolic inhibitors for the treatment of blood-borne cancers.

Authors:  Martin Villalba; Nuria Lopez-Royuela; Ewelina Krzywinska; Moeez G Rathore; Robert A Hipskind; Houda Haouas; Nerea Allende-Vega
Journal:  Anticancer Agents Med Chem       Date:  2014-02       Impact factor: 2.505

Review 2.  Targeted Therapies in Adult B-Cell Malignancies.

Authors:  Jean-François Rossi
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

3.  Leukemia cells induce changes in human bone marrow stromal cells.

Authors:  Sara Civini; Ping Jin; Jiaqiang Ren; Marianna Sabatino; Luciano Castiello; Jianjian Jin; Huan Wang; Yuanlong Zhao; Francesco Marincola; David Stroncek
Journal:  J Transl Med       Date:  2013-12-04       Impact factor: 5.531

4.  Mitochondrial oxidative phosphorylation is dispensable for survival of CD34+ chronic myeloid leukemia stem and progenitor cells.

Authors:  Jin-Song Yan; Meng-Ying Yang; Xue-Hong Zhang; Chen-Hui Luo; Cheng-Kan Du; Yue Jiang; Xuan-Jia Dong; Zhang-Man Wang; Li-Xue Yang; Yi-Dong Li; Li Xia; Ying Lu
Journal:  Cell Death Dis       Date:  2022-04-20       Impact factor: 9.685

5.  Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.

Authors:  Octavian Bucur; Andreea Lucia Stancu; Ioana Goganau; Stefana Maria Petrescu; Bodvael Pennarun; Thierry Bertomeu; Rajan Dewar; Roya Khosravi-Far
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

6.  Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang.

Authors:  Hong-Sheng Zhou; Bing Z Carter; Michael Andreeff
Journal:  Cancer Biol Med       Date:  2016-06       Impact factor: 4.248
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.